Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review

Anastasios Kyriazoglou; Maria Kaparelou; G. Goumas; Michalis Liontos; Roubini Zakopoulou; Eleni Zografos; Anna Zygogianni; Meletios A Dimopoulos; Flora Zagouri

doi:10.1159/000514860

Related publications

Article2025

Immunotherapy in primary hormone-receptor positive breast cancer: A systematic review

Maria‐Theodora Melissari, Alkistis Papatheodoridi, Athanasios Argyriadis, Kolliopoulou Maria, Meletios A Dimopoulos, Flora Zagouri

Article2014

Low protein expression of MET in ER-positive and HER2-positive breast cancer.

Flora Zagouri, Anita Brandstetter, Dimitrios Moussiolis, Dimosthenis Chrysikos, Constantine Dimitrakakis, Alexandra Tsigginou, Spyridon S Marinopoulos, George Zografos, Theodoros Ν. Sergentanis, Meletios A Dimopoulos, Martin Filipits

Article2014

Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice

Martina Bonifazi, Matteo Franchi, Marta Rossi, Alberto Zambelli, Lorenzo Moja, Antonella Zambon, Giovanni Corrao, Carlo La Vecchia, Carlo Zocchetti, Eva Negri

Article2016

Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models

Sònia Palomeras, Ángel Díaz‐Lagares, Ariadna Sarrats, Crujeiras Ana Belen, Ariadna Giró‐Perafita, Juan Sandoval, Marc Rabionet, Manel Esteller, Teresa Puig

Article2020

Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review

Oraianthi Fiste, Michalis Liontos, Konstantinos Koutsoukos, Evangelos Terpos, Meletios A Dimopoulos, Flora Zagouri